Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa

Journal of Infectious Diseases

Volumn 199, Issue 9, 2009, Pages 1360-1368

  Beernink, P T ^a   Caugant, D A ^b   Welsch, J A ^a   Koeberling, O ^a   Granoff, D M ^a,c  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; COMPLEMENT FACTOR H; EPITOPE; MONOCLONAL ANTIBODY; OUTER MEMBRANE VESICLE VACCINE; UNCLASSIFIED DRUG;

AFRICA; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIGENIC VARIATION; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; EPIDEMIC; HUMAN; INFECTION SENSITIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN VARIANT;

EID: 65649149729     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/597806     Document Type: Article

References (53)

1. Greenwood B. Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 1999; 93:341-53.
2. World Health Organization. WHO report on global surveillance of epidemic-prone diseases. 2001. Available at: http://www.who.int/csr/ resources/publications/surveillance/WHO-CDS-CSR-ISR-2000-1/en/. Accessed 16 March 2009.
3. Miller MA, Wenger J, Rosenstein N, Perkins B. Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa. Pediatr Infect Dis J 1999; 18:1051-9.
4. LaForce FM, Konde K, Viviani S, Préziosi MP. The Meningitis Vaccine Project. Vaccine 2007; 25(Suppl 1):A97-100.
5. Jodar L, LaForce MF, Ceccarini C, Aguado MT, Granoff DM. Meningococcal conjugate vaccine for Africa: a model for developing new vaccines for the poorest countries. Lancet 2003; 361:4997-9.
6. Mueller JE, Borrow R, Gessner BD. Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines. Expert Rev Vaccines 2006; 5:319-36.
7. Boisier P, Nicolas P, Djibo S, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007; 44:657-63.
8. Gagneux SP, Hodgson A, Smith TA, et al. Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis 2002; 185:618-26.
9. De Groot AS, Rappuoli R. Genome-derived vaccines. Expert Rev Vaccines 2004; 3:59-76.
10. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000; 287:1816-20.
11. Williams JN, Skipp PJ, Humphries HE, Christodoulides M, O'Connor CD, Heckels JE. Proteomic analysis of outer membranes and vesicles from wildtype serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant. Infect Immun 2007; 75:1364-72.
12. Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factorHand enhances serum resistance. J Immunol 2006; 177:501-10.
13. Schneider MC, Exley RM, Chan H, et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 2006; 176:7566-75.
14. Welsch JA,RamS, Koeberling O, Granoff DM. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 2008; 197:1053-61.
15. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad SciUSA2006; 103:10834-9.
16. Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004; 72:2088-100.
17. Comanducci M, Bambini S, Brunelli B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002; 195:1445-54.
18. Beernink PT, Welsch JA, Harrison LH, Leipus A, Kaplan SL, Granoff DM. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J Infect Dis 2007; 195:1472-9.
19. Welsch JA, Moe GR, Rossi R, Adu-Bobie J, Rappuoli R, Granoff DM. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 2003; 188:1730 - 40.
20. Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003; 197:789-99.
21. Hou VC, Koeberling O, Welsch JA, Granoff DM. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J Infect Dis 2005; 192:580-90.
22. Koeberling O, Seubert A, Granoff DM. Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis 2008; 198:262-70.
23. Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 1998; 95:3140-5.
24. Neisseria MLST Home Page. Available at: http://pubmlst.org/neisseria. Accessed 23 February 2009.
25. Neisseria.org Home Page. Available at: http://neisseria.org. Accessed 23 February 2009.
26. Beernink PT, Leipus A, Granoff DM. Rapid genetic grouping of factor H-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin Vaccine Immunol 2006; 13:758-63.
27. Neisseria.org fHbp Database. Available at: http://neisseria.org/perl/ agdbnet/agdbnet.pl?file-nm-fhbp.xml&page-browse&locus-public- FHBP-p. Accessed 23 February 2009.
28. Welsch JA, Rossi R, Comanducci M, Granoff DM. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol 2004; 172:5606-15.
29. Wang JF, Caugant DA, Li X, et al. Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China. Infect Immun 1992; 60:5267-82.
30. Moe GR, Zuno-Mitchell P, Hammond SN, Granoff DM. Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun 2002; 70:6021-31.
31. Beernink PT, Welsch JA, Bar-Lev M, Koeberling O, Comanducci M, Granoff DM. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor H-binding protein. Infect Immun 2008; 76:4232-40.
32. Koeberling O, Giuntini S, Seubert A, Granoff DM. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H-binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol 2009; 16:156-62.
33. Fredriksen JH, Rosenqvist E, Wedege E, et al. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 1991; 14:67-79; discussion, 79-80.
34. Welsch JA, Granoff D. Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal activity. Clin Vaccine Immunol 2007; 14:1596-602.
35. Bentley SD, Vernikos GS, Snyder LA, et al. Meningococcal genetic variation mechanisms viewed through comparative analysis of serogroup C strain FAM18. PLoS Genet 2007; 3:e23.
36. Nicolas P, Norheim G, Garnotel E, Djibo S, Caugant DA. Molecular epidemiology of Neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol 2005; 43:5129-35.
37. Koumare B, Ouedraogo-Traoré R, Sanou I, et al. The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine 2007; 25(Suppl 1):A37-41.
38. Mueller JE, Sangaré L, Njanpop-Lafourcade BM, et al. Molecular characteristics and epidemiology of meningococcal carriage, Burkina Faso, 2003. Emerg Infect Dis 2007; 13:847-54.
39. Gagneux S, Wirth T, Hodgson A, et al. Clonal groupings in serogroup X Neisseria meningitidis. Emerg Infect Dis 2002; 8:462-6.
40. Materu S, Cox HS, Isaakidis P, Baruani B, Ogaro T, Caugant DA. Serogroup X in meningococcal disease, Western Kenya. Emerg Infect Dis 2007; 13:944-5.
41. Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008; 299:173-84.
42. Nathan N, Rose AM, Legros D, et al. Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis 2007; 13:920-3.
43. Mueller JE, Yaro S, Traore Y, et al. Neisseria meningitidis serogroups A and W-135: carriage and immunity in Burkina Faso, 2003. J Infect Dis 2006; 193:812-20.
44. Koeberling O, Welsch JA, Granoff DM. Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870. Vaccine 2007; 25:1912-20.
45. Frasch C, Van Alphen L, Holst J, Poolman J, Rosenqvist E. Outer membrane protein vesicle vaccines for meningococcal disease. In: Pollard AJ, Maiden MC, eds. Meningococcal vaccines: methods and protocols. Totowa, New Jersey: Humana Press, 2001:81-107.
46. van der Ley P, Steeghs L, Hamstra HJ, ten Hove J, Zomer B, van Alphen L. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun 2001; 69:5981-90.
47. Kelly C, Arnold R, Galloway Y, O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007; 166:817-23.
48. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338:1093-6.
49. Holst J, Feiring B, Naess LM, et al. The concept of "tailor-made, " protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005; 23:2202-5.
50. Taha MK, Zarantonelli ML, Alonso JM, et al. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. Vaccine 2007; 25:2537-8.
51. Holst J. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Hum Vaccin 2007; 3:290-4.
52. Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5 year olds in New Zealand. Vaccine 2007; 25:3075-9.
53. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999; 281:1520-7.